Marksans Pharma Limited has informed the Exchange regarding a press release dated May 19, 2025, titled "Press Release dated 19 May 2025 regarding audited financial results for the quarter and year ended 31 March 2025".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma reported record-high annual revenue and profits for FY25. Operating revenue grew 20.5% YoY to Rs. 2,622.8 cr, while PAT rose 21.5% to Rs. 382.6 cr, with EPS at Rs. 8.4. The US business was the key growth driver, expanding 34.7% YoY to Rs. 1,236.6 cr, while UK & Europe grew 9.2% and Australia/NZ rose 15.5%. For Q4FY25, revenue jumped 26.5% YoY to Rs. 708.5 cr and EBITDA grew 14.7% to Rs. 125.8 cr. Gross margin expanded sharply by 407 bps YoY to 56.4% for the full year, helped by lower raw material costs and a better product mix. The company also commercialized 58 products in the US and has 79 products in its US pipeline.
A clean beat across revenue, profits, and margins — led by strong US growth and expanding gross margins — is positive for the stock. Robust cash balance of Rs. 704.2 cr and ongoing capex on the Goa facility support the growth outlook.